Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05130060CT.gov A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectum Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Polypepi1018 (this asset) | Mayo Clinic | P1 | CC · 47 |
| Fluorouracilum | Merck Sharp & Dohme LLC | P3 | BBB |
| Irinotecan | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BBB |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Pertuzumab | SWOG Cancer Research Network | P2 | BB |
| Regorafenib | City of Hope Medical Center | P2 | BB |
| Trifluridine | Sir Run Run Shaw Hospital | P2 | BB |
| Tipiracil | Sir Run Run Shaw Hospital | P2 | BB |
+42 more in the Rectum Adenocarcinoma cohort
Other indications for Polypepi1018
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P1/2 | CCC · 52 |
| Metastatic Malignant Neoplasm In The Colon | — | P2 | CCC · 48 |
| Colon Adenocarcinoma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Polypepi1018 in Rectum Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/polypepi1018-rectum-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →